---
schema_version: "secwatch.filing_event.v1"
accession: "0001040130-24-000043"
form_type: "8-K"
ticker: "PETS"
cik: "0001040130"
company_name: "PETMED EXPRESS INC"
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T04:58:27.765711+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PetMed Express Q4 net loss widens to $5.0M; FY net loss $7.5M vs prior year profit

## Summary
- Q4 net sales $66.5M (+6.6% YoY) driven by PetCareRx acquisition; legacy PetMeds sales declined.
- Q4 net loss $5.0M ($0.25 diluted EPS) vs loss $0.2M ($0.01) in prior year quarter.
- FY 2024 net loss $7.5M ($0.37 diluted EPS) vs net income $5.1M ($0.25) in FY 2023.
- Adjusted EBITDA Q4 $0.5M (from $3.6M); FY $8.2M (from $19.8M) as G&A and marketing rose.
- CEO cites challenging macro environment and new Order Management System slowdown in Q4.

## SEC filing metadata
- accession: 0001040130-24-000043
- form_type: 8-K
- ticker: PETS
- cik: 0001040130
- company_name: PETMED EXPRESS INC
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1040130/000104013024000043/0001040130-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1040130/000104013024000043/pets-20240611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001040130-24-000043
- JSON: https://secwatch.observer/filing/0001040130-24-000043.json
- Plain text: https://secwatch.observer/filing/0001040130-24-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.